Viatris announced that it has closed the divestiture of its Over-the-Counter, OTC, business to Cooper Consumer Health, bringing to substantial completion all previously announced divestitures. In October, the Company announced it had entered into agreements to divest substantially all of its OTC business, as well as its Women’s Healthcare business, its Active Pharmaceutical Ingredients business in India and commercialization rights in certain non-core markets. The completion of the OTC divestiture is a major milestone in the execution of the Company’s strategic plan to considerably simplify the organization in order to increase focus on areas with the greatest potential to accelerate growth, patient impact and shareholder value. The transaction includes two manufacturing sites located in Merignac, France, and Confienza, Italy, and a Research & Development site in Monza, Italy. The Company is retaining rights for Viagra, Dymista and select OTC products in certain markets. The transaction closed on July 3, 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTRS:
- Division of U.S. DOJ no longer considers Mylan subject of investigation
- Regeneron price target raised to $1,125 from $1,050 at Wells Fargo
- Viatris Inc. Expands Board and Welcomes New Expert Director
- Viatris lowers FY24 adjusted EPS view to $2.66-$2.81 from $2.70-$2.85
- Viatris reports Q1 adjusted EPS 67c, consensus 67c